Building Long-term Capacity for HIV/AIDS in Africa: S-S and Regional Strategies
|
|
- William Berry
- 5 years ago
- Views:
Transcription
1 Building Long-term Capacity for HIV/AIDS in Africa: S-S and Regional Strategies Quarraisha Abdool Karim, PhD Director: CU-SA Fogarty AITRP Institute of Medicine (IOM) Envisioning a Strategy to Prepare for the Long-Term Burden of HIV/AIDS: African Needs and U.S. Interests April in Pretoria, South Africa.
2 Life in the 21 st Century
3 Going to battle with sticks and stones
4 Need to diversify prevention research portfolio Tenofovir Truvada
5 Strengthening the Science Base in 58 countries SSA - the Challenge! Majority with no Medical Schools or Schools of Public Health Limited research infrastructure Limited science base Nurse driven health services Getting to S-S a long, but not insurmountable journey Institute of Medicine (IOM) Envisioning a Strategy to Prepare for the Long-Term Burden of HIV/AIDS: African Needs and U.S. Interests April in Pretoria, South Africa.
6 The CU-SA Fogarty AITRP: A Tale of Evolving Politics, Epidemics & Science:
7 Building capacity - Evolving politics, evolving challenges and evolving responses Apartheid democracy Respectful partnerships CU and SA, SADC AITRP 3 cycles changing leadership Building capacity people and institutions high end, research, create opportunities Translational and operational Grants, Units, Centres, CIPRA MDGs LE, MMR, IMR HIV&TB Generate and share knowledge Increase $ for research
8 CU-SA Fogarty AITRP South Africa pre-1990: no schools of public health and 5 foreign trained epidemiologists Limited capacity to respond to HIV/TB 2010 : highest number of NIH grants outside US strong internationally recognised scientific leadership critical mass of scientists across disciplines major centres of excellence across the country Strong partnerships and collaborative relationships Regional and S-S resource Not sufficient to turn epidemic around! Limited local investments in capacity building Fragility of institutions Balance between multi-centre studies vs locally relevant research Institute of Medicine (IOM) Envisioning a Strategy to Prepare for the Long-Term Burden of HIV/AIDS: African Needs and U.S. Interests April in Pretoria, South Africa.
9 CU-SA Fogarty AITRP: HIV & TB Training in US and SA Basic science, epidemiology, ethics and social sciences 125 long-term traineeships 84 (67%) are women 85 (68%) from previously disadvantaged communities 40 long-term USA Trainees: 21 obtained MS (Epi) degrees, 3 MPHs 2 obtained MS (Biostatistics) degrees, 1 MS (Health Sciences) 2 currently in training 11 PhDs 186 Short-term traineeships range of labs across USA Institute of Medicine (IOM) Envisioning a Strategy to Prepare for the Long-Term Burden of HIV/AIDS: African Needs and U.S. Interests April in Pretoria, South Africa.
10 CU-SA Fogarty AITRP: (2) > 99% Retention Rate Leveraging Additional Funds for Training FIC Supplements LifeLab, KRITH, CIPRA Ongoing training and capacity building through local workshops 46 co-sponsored conferences and workshops in South Africa Training in Swaziland, Lesotho and Namibia > 7000 local participants > 1000 publications in high impact journals Numerous NIH grants Numerous Centres, Institutes and Units Leadership role at highest levels locally and globally
11 CU-SA Fogarty AITRP : North-South CU-SA Fogarty AITRP established in epidemiologists in South Africa (all trained outside South Africa) and no Schools of Public Health Challenges faced by CU-SA Fogarty AITRP: Apartheid isolation Few international funding opportunities to SA scientists Lack of public health research training opportunities in SA Rapidly growing HIV epidemic HIV prevalence < 5% Steering Committee CU & SA SPHs Local PI appointment at CU Respectful partnership Regional resource Trainees from Lesotho, Swaziland, Namibia, Botswana 25 South African institutions National and Provincial Health Departments, MRC, Research Centres and Universities
12 CU-SA Fogarty AITRP : N-S, S-N Program s role in successful NIH applications involving trainees: HIVNET units; HPTN unit and HVTN unit; 2 CIPRA program awards;2 PACTG satellite units; 2 AACTG satellite units; 3 social science partnership research awards; ICOHRTA planning award UKZN alone - about $20million in NIH grants during this period Sub-contracts with US institutions Steering Committee expansion beyond SPH and CU in SA and US Generating & Participating in RCTs GRIPP? HIV Epidemic continues to grow AIDS denialism
13
14 HIV prevention trial landscape in 2006 Microbicide Barrier Behaviour Treatment pmtct Vaccine Population Council Carraguard HVTN 204 HPTN 035: Pro 2000 & Buffergel CDC Truvada PrEP trial: Heterosexual HVTN 503 trial PAVE 100 trial HPTN 039 HSV-2 Susceptibility UCSF MIRA Diaphragm NIMH Project Accept trial: Community based VCT MDP 301 Pro % and 5% Trial CAPRISA 004: Tenofovir gel trial HPTN Estimated trial completion date
15 CU-SA Fogarty AITRP : N-S, S-N, S-S Substantial increase in # of Institutes, Centres, Units but fragile Increasing opportunities for training in SA degree courses and practical experience Local and international students (US and RCS) China, Saudi Arabia, India, Uganda, Ethiopia, SC includes two previous trainees CIPRAs - strong base for locally important research; Network research Epidemic grows, denialism, Availability of ARVS
16 CU-SA Fogarty AITRP : N-S, S-N, S-S Strengthen Institutes, Centres, Units Strengthen training in South Select high level training in US Expand S-S collaboration SC expansion to > representation from south + previous trainees End of HIV denialism demand for implementation science HIV & TB epidemics intertwined
17 Why S-S Collaboration is important Develops local research capacity Not just for HIV, but also for other emerging health threats Helps to reduce the Brain Drain Building research infrastructure helps reduce brain drain Contributes to better understanding of the HIV epidemic and its nuances in a broader range of settings
18 CU-SA Fogarty AITRP (2) Base for building other training programs FICRS Implementation science Expansion to other Infectious and noninfectious diseases eg KS Institutional bases for S-S collaboration and training opportunities Balance between local vs international training Leverage for other training resources Institute of Medicine (IOM) Envisioning a Strategy to Prepare for the Long-Term Burden of HIV/AIDS: African Needs and U.S. Interests April in Pretoria, South Africa.
19 Goal Build next generation of scientific leadership globally Strengthen institutional capacity for training and research Support existing faculty Build critical mass Career paths Rewards for focus on priority research Be responsive to changing needs Institute of Medicine (IOM) Envisioning a Strategy to Prepare for the Long-Term Burden of HIV/AIDS: African Needs and U.S. Interests April in Pretoria, South Africa.
Update on PrEP progress: WHO/UNAIDS challenges and actions
Update on PrEP progress: WHO/UNAIDS challenges and actions Kevin R. O'Reilly Prevention in the Health Sector, HIV/AIDS Department, WHO HQ Outline Review current status of PrEP Planning for PrEP Pre-exposure
More informationUpdate on ARV based PrEP
Update on ARV based PrEP Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw Controlling HIV
More informationInvesting for Impact
Global Fund Strategic Framework: Investing for Impact M&E: Capturing data to improve services Workshop to Scale Up the Implementation of Collaborative TB/HIV Activities in Africa 10-11 April, 2013; Maputo,
More informationAntiretrovirals for HIV prevention:
Antiretrovirals for HIV prevention: Topical PrEP, Systemic PrEP and Treatment for Prevention Presentation at 6th International workshop on HIV treatment, pathogenesis and prevention research in resource-limited
More informationFogarty Initiatives for Building Capacity in HIV/AIDS
Fogarty Initiatives for Building Capacity in HIV/AIDS April 13, 2010 Michael P. Johnson, M.D., M.P.H Deputy Director Fogarty International Center Global Health Transition in 21 st Century the unfinished
More informationOn the Horizon for Consideration: Biomedical Advances in HIV Prevention
On the Horizon for Consideration: Biomedical Advances in HIV Prevention Francisco Ruiz, MS Senior Manager, National Alliance of State and Territorial AIDS Directors New Jersey Governor's Advisory Council
More informationM2010 Pre-Conference Workshop, Pittsburgh 22 May 2010
HIV Prevention Research: The Global Picture Presented at: M2010 Pre-Conference Workshop, Pittsburgh 22 May 2010 Salim S. Abdool Karim Pro Vice-Chancellor (Research): University of KwaZulu-Natal Director:
More informationCAN MONEY REDUCE HIV RISK?? Audrey Pettifor, PhD MPH Department of Epidemiology, University of North Carolina
CAN MONEY REDUCE HIV RISK?? Audrey Pettifor, PhD MPH Department of Epidemiology, University of North Carolina Overview Epidemiology of HIV in young people Rationale behind cash transfers Review completed
More informationARVs for prevention in at-risk populations: Microbicides
ARVs for prevention in at-risk populations: Microbicides Treatment as Prevention in Africa Meeting Botswana, April 30 May 3, 2014 Salim S Abdool Karim Director: CAPRISA Pro Vice-Chancellor (Research):
More informationNovel HIV Prevention Methods for Women
Novel HIV Prevention Methods for Women State of the art injectables, rings, and antibody-mediated prevention Nyaradzo M Mgodi (MBChB, MMed) Principal Investigator University of Zimbabwe- College of Health
More informationDoing studies of ARV based
Doing studies of ARV based microbicides what s s different, what s s the same? Gonasagrie Nair, MBChB, DTM&H, MPH CAPRISA ethekwini Site Project Director & IoR VOICE Trial OVERVIEW Brief historical overview
More informationPrEP May Cause a Revolution in HIV Prevention: Time to Get Ready
PrEP May Cause a Revolution in HIV Prevention: Time to Get Ready Thomas J. Coates PhD Michael and Sue Steinberg Professor of Global AIDS Research David Geffen School of Medicine University of California,
More informationLearning from the past: How prepared are we for future HIV vaccine efficacy trials in Uganda
Learning from the past: How prepared are we for future HIV vaccine efficacy trials in Uganda Pontiano Kaleebu MRC-UVRI Uganda Research Unit on AIDS & UVRI-IAVI HIV Vaccine Programme Past 1987 Cohort studies
More informationInspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel
Inspiring HIV Prevention Innovations for Women IPM Satellite Event Durban, 13 th June 2017 Annalene Nel HIV Infection: Where We Are Today 30+ years since the US CDC reported the first cases of AIDS 25.5
More informationETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF
ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF PrEP MTN Regional Meeting Cape Town 20 September 2017 Dhevium Govender South African Medical Research Council HIV Prevention Research Unit Quality/Regulatory
More informationRenewing Momentum in the fight against HIV/AIDS
2011 marks 30 years since the first cases of AIDS were documented and the world has made incredible progress in its efforts to understand, prevent and treat this pandemic. Progress has been particularly
More informationHIV Prevention Strategies HIV Pre-exposure prophylaxis
HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those
More informationInternational Partnership for Microbicides
International Partnership for Microbicides Advancing HIV Prevention Options for Women GNP+ Consultation on NPTs Thomas Mertenskoetter 5. 6. July 2010, Amsterdam Leading Causes of Death in Women (Age 15
More informationCombination HIV Prevention
Combination HIV Prevention Timothy Mastro, MD, FACP, DTM&H FHI 360, Durham, North Carolina, USA 7 th INTEREST Workshop, Dakar, Senegal 15 May 2013 Outline What Works for HIV Prevention? Highly Active
More informationFuture Challenges for Research
Future Challenges for Research HIV Epidemic in Southeastern U.S. Role of the NIH Office of AIDS Research 2nd Annual TN-CFAR Workshop Nashville, TN March 24, 2017 Maureen M. Goodenow, Ph.D. Associate Director
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More informationOkinawa, Toyako, and Beyond: Progress on Health and Development
Okinawa, Toyako, and Beyond: Progress on Health and Development Prof. Michel D. Kazatchkine Executive Director The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations University, Tokyo,
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Diagnosis and promotion of serostatus awareness in sub-saharan Africa 1. Antiretroviral therapy reduces HIV transmission from a HIV- positive person to a susceptible
More informationInternational Partnership for Microbicides
International Partnership for Microbicides New Directions in Microbicide Research Accelerating an HIV Prevention Revolution: A Roadmap Zeda F. Rosenberg, ScD, Chief Executive Officer Washington, DC, March
More informationHIV In South Africa: Turning the Tide of the Epidemic
HIV In South Africa: Turning the Tide of the Epidemic Jean B. Nachega, MD, PhD Associate Professor Department of Epidemiology Pittsburgh University, Graduate School of Public Health E-mail: JBN16@PITT.EDU
More informationElimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive:
Elimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive: Rationale for the call to action, progress to date and dealing with realities Rene Ekpini, MD, MPH Senior Adviser,
More informationUnderstanding the Results of VOICE
CONTACT: Lisa Rossi +1-412- 916-3315 (mobile) or +27-(0)73-323-0087 (through 7 March) rossil@upmc.edu About VOICE Understanding the Results of VOICE VOICE Vaginal and Oral Interventions to Control the
More informationProgress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa
SUMMARY REPORT Progress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa January December 2012 Table of contents List of acronyms 2 Introduction 3 Summary
More informationACHAP LESSONS LEARNED IN BOTSWANA KEY INITIATIVES
ACHAP Together with our company s foundation, a U.S.-based, private foundation, and the Bill & Melinda Gates Foundation, we established the African Comprehensive HIV/AIDS Partnerships (ACHAP) in 2000 to
More informationGood Things that Pharma Companies Do
Good Things that Pharma Companies Do Mark W. Kline, M.D. Professor and President Baylor International Pediatric AIDS Initiative Baylor College of Medicine Texas Children s Hospital New Pediatric AIDS Cases,
More informationThe Big Picture: The current and evolving HIV prevention landscape
The Big Picture: The current and evolving HIV prevention landscape Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking stakeholder perspectives on next steps with the for HIV
More informationWOMEN & HIV: A GLOBAL UPDATE. Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society
WOMEN & HIV: A GLOBAL UPDATE Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society Objectives Review the current global burden of HIV among women Trends and progress to date Groups with
More informationHIV Drug Resistance Regional Update Eastern & Southern African Region
HIV Drug Resistance Regional Update Eastern & Southern African Region Dr R Banda, IST/ESA Dr F Cham, IST/ESA Dr RG Vaz, WHO AFRO HIVDR Steering Committee Meeting, Geneva 11-12 November 2009 1 Presentation
More informationUsing anti-hiv drugs for prevention
Using anti-hiv drugs for prevention Highlights from AIDS 2012 (and 2 nd International Workshops on Treatment as Prevention) Tim Rogers, trogers@catie.ca Using anti-hiv Drugs for Prevention Outline Treatment
More informationThe Big Picture: The current and evolving HIV prevention landscape
The Big Picture: The current and evolving HIV prevention landscape Sharon Hillier, Ph.D. University of Pittsburgh Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine
More informationART for prevention the task ahead
ART for prevention the task ahead Dr Teguest Guerma WHO/HQS WHO's role and vision Status of the epidemic Overview Progress and challenges in treatment and prevention scale up ART for prevention Questions
More informationSuccessful results of clinical trials
Successful results of clinical trials Four clinical trials for HIV prevention in past two years showed different degrees of efficacy > HPTN 052 showed 96% reduction in HIV transmission from HIV infected
More informationScaling up priority HIV/AIDS interventions in the health sector
TOWARDS UNIVERSAL ACCESS? Scaling up priority HIV/AIDS interventions in the health sector Yves Souteyrand, WHO October 2011 Towards universal access targets UN General Assembly High level Meeting June
More informationSAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL
SAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL Glenda Gray President & CEO SAMRC 1 SA AIDS 2017 Durban 15 June 2017 Partner logo LEADERSHIP IN A TIME OF UNCERTAINTY 2 BASELINE BUDGET
More informationSave the Children President s Emergency Plan OVC Programming. Stacy Rhodes Director, HIV/AIDS Office April 19th, 2005
Save the Children President s Emergency Plan OVC Programming Stacy Rhodes Director, HIV/AIDS Office April 19th, 2005 Presentation Overview OVC Situation Save the Children HIV/AIDS Office programs USG Emergency
More information7.5 South-East Asian Region: summary of planned activities, impact and costs
PART II: GLOBAL AND REGIONAL SCENARIOS FOR TB CONTROL 26 215 7.5 South-East Asian Region: summary of planned activities, impact and costs Achievements DOTS expanded rapidly in the South-East Asian Region
More informationThe World Bank Group s Engagement in Tuberculosis Control Background Document Prepared for the Stop TB Partnership Board Meeting November 2015
Background The World Bank Group s Engagement in Tuberculosis Control Background Document Prepared for the Stop TB Partnership Board Meeting November 2015 Historically, the World Bank has supported a wide
More informationPost-2015 TB Elimination Strategy and Targets
Photo: Riccardo Venturi Vision and proposed framework for a Post-2015 TB Elimination Strategy and Targets Consultation on Eliminating the catastrophic economic burden of TB" Universal Health Coverage and
More informationHIV Prevention. Recent Advances and Implications for the Caribbean
HIV Prevention Recent Advances and Implications for the Caribbean Chris Behrens, MD CCAS/CHART Conference Barbados, August 2010 Cases 200 180 160 140 120 100 80 60 40 20 0 Year HIV Cases AIDS Cases HIV
More informationBiomedical Prevention in HIV
Biomedical Prevention in HIV CHART - CCAS-CDC 3 RD Joint Meeting Montego Bay, Jamaica August 21-26,2011 Presented by Tina Hylton-Kong, ERTU-CHART Some Slides from Impact of ART on HIV Transmission Wafaa
More informationPre-Exposure Topical Microbicides and Oral Prophylaxis Trials:
Pre-Exposure Topical Microbicides and Oral Prophylaxis Trials: Rationale, Designs & Issues Connie Celum, MD, MPH Patrick Ndase, MBChB, MPH May 2007 Regional MTN Meeting Importance of HIV prevention Antiretroviral
More informationExpanding ART South Africa -Challenges and a SWOT analysis Umesh G Lalloo
Expanding ART South Africa -Challenges and a SWOT analysis Umesh G Lalloo Nelson R Mandela School of Medicine College of Health Sciences STANDARD CARE SERVICES FOR HIV/AIDS* Palliative Care Home-based
More informationAFRICAN PLAN TOWARDS THE ELIMINATION OF NEW HIV INFECTIONS AMONG CHILDREN BY 2015 AND KEEPING THEIR MOTHERS ALIVE
AFRICAN PLAN TOWARDS THE ELIMINATION OF NEW HIV INFECTIONS AMONG CHILDREN BY 2015 AND KEEPING THEIR MOTHERS ALIVE Contents Foreword 4 List of abbreviations and acronyms 5 Introduction 6 Background 6 Rationale
More informationStrategic use of antiretroviral drugs to prevent HIV transmission
Strategic use of antiretroviral drugs to prevent HIV transmission 22th Tunisian Congress of Infectious Diseases 2nd Congress of Federation of Arab Societies of Clinical Microbiology and Infectious Diseases
More informationFAST-TRACK: HIV Prevention, treatment and care to End the AIDS epidemic in Lesotho by 2030
Evidence informed, responsive and sustainable care FAST-TRACK: HIV Prevention, treatment and care to End the AIDS epidemic in Lesotho by 2030 Alti Zwandor UNAIDS Country Director Maseru, Lesotho 9 December
More informationHIV DIAGNOSTIC TESTS IN LOW- AND MIDDLE-INCOME COUNTRIES: FORECASTS OF GLOBAL DEMAND FOR
HIV DIAGNOSTIC TESTS IN LOW- AND MIDDLE-INCOME COUNTRIES: FORECASTS OF GLOBAL DEMAND FOR 2015 2020 Presented by Vincent Habiyambere (WHO), Biyi Adesina (Avenir Health) and Meghan Wareham (CHAI) on behalf
More informationPartners for Health Reformplus. Strengthening Health System Responses to HIV/AIDS
Partners for Health Reformplus Strengthening Health System Responses to HIV/AIDS Summary o Costing HIV/AIDS Treatment Services As countries begin to seriously explore introducing antiretroviral (ARV) treatment
More informationInternational Partnership for Microbicides
International Partnership for Microbicides Female-Initiated Prevention: State of the Art Dr. Zeda F. Rosenberg German-Austrian AIDS Congress Frankfurt, Germany 29 June 2007 Women s Vulnerability to HIV
More informationProgress in scaling up HIV prevention and treatment in sub-saharan Africa: 15 years, the state of AIDS
10 th International Workshop on HIV treatment, Pathogenesis and Prevention Research in Resource-Limited setting (INTEREST, 3-6 May, 2016) Progress in scaling up HIV prevention and treatment in sub-saharan
More informationAntiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?
Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated
More informationPre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:
Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women: Coming of Age Aaron Kofman, BA, MD 14 Eli Y. Adashi, MD, MS, CPE, FACOG BRIGHT Series June 12, 2012 Women and the HIV Epidemic Global
More informationZero HIV infections Zero HIV deaths Zero HIV stigma. Stephanie Cohen, MD, MPH on behalf of the Getting to Zero Consortium
Zero HIV infections Zero HIV deaths Zero HIV stigma Stephanie Cohen, MD, MPH on behalf of the Getting to Zero Consortium Number of New HIV Diagnoses Overall decline in new HIV diagnoses and death in San
More informationWHO HIV Drug Resistance Prevention and Assessment Strategy. Dr Richard Banda Technical Officer, HIV Drug Resistance WHO Inter-country Support Team
WHO HIV Drug Resistance Prevention and Assessment Strategy Dr Richard Banda Technical Officer, HIV Drug Resistance WHO Inter-country Support Team Eastern & Southern African Countries (ESA) 2 The HIV epidemic
More informationHP+/Project SOAR Oral PrEP Modeling. Webinar Series: Five Ways to Accelerate Progress Toward the Goals January 16, 2018
HP+/Project SOAR Oral PrEP Modeling Webinar Series: Five Ways to Accelerate Progress Toward the 95-95-95 Goals January 16, 2018 Activity Overview 2 Activity Objective Provide impact, cost, and cost-effectiveness
More informationQUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE 1. What is the Partners PrEP study? The Partners PrEP Study is a double-blind,
More informationTB in the Southern African mining sector and across the sub-region STOP TB Partnership Board Meeting By Dr Aaron Motsoaledi Minister of Health South
TB in the Southern African mining sector and across the sub-region STOP TB Partnership Board Meeting By Dr Aaron Motsoaledi Minister of Health South Africa 1 Framing the Public Health Challenge Africa
More informationRectal Microbicides: The Basics. Date, Location Your name, Your affiliation
Rectal Microbicides: The Basics Date, Location Your name, Your affiliation This presentation Who is IRMA? Overview of the HIV epidemic New prevention technologies What are microbicides? Why do we need
More informationHigh Level Regional Consultation for Policy Makers to Enhance Leadership in Planning the National HIV & AIDS Response. HIV Prevention (PM1S4)
High Level Regional Consultation for Policy Makers to Enhance Leadership in Planning the National HIV & AIDS Response HIV Prevention (PM1S4) Tomas Lundstrom UNAIDS RST/ESA Overview Prioritization Low level
More informationAnticipating ethical concerns during disaster research: perspectives from South Africa
Anticipating ethical concerns during disaster research: perspectives from South Africa Prof Keymanthri Moodley Bioethics Unit Tygerberg division Centre For Applied Ethics & Faculty of Health Sciences University
More informationthe Office of Research Application Portal: Materials to submit:
Title: PAR 17 237: Centers for AIDS Research (P30) Slots: 1 Internal Deadline: LOI: External Deadline: Award Information: Submission Process: May 26, 2018, 5pm PDT 30 days prior to the application due
More informationPolicies for VMMC in 14 priority countries of east and southern Africa
Policies for VMMC in 14 priority countries of east and southern Africa Andre Verani, JD, MPH Senior Policy Analyst Division of Global HIV and TB Centers for Disease Control and Prevention, Atlanta, USA
More informationEducational Challenges in Building the Health Infrastructure to Combat HIV/AIDS
Educational Challenges in Building the Health Infrastructure to Combat HIV/AIDS Durban LSON R. MANDELA SCHOOL OF MEDICINE rtnerships towards enhanced Health in Africa We must meet the challenge of expanding
More informationPRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT
PRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT Dr Chewe Luo MMed (Paeds), Mtrop Paed, PhD Senior Adviser and Team Leader Country Programme Scale up HIV Section Programme Division UNICEF, NY
More informationExperiences on Workforce Development in Other Regions
Experiences on Workforce Development in Other Regions The USA Experience John MacArthur, MD, MPH (EIS 98) Director Thailand MOPH US CDC Collaboration CDC/Southeast Asia Regional Office Epidemic Intelligence
More informationDirect from Delhi: Microbicides2008 Comes to Sweet Home Chicago
Direct from Delhi: Microbicides2008 Comes to Sweet Home Chicago Microbicide Pipeline Update Latifa Boyce Alliance for Microbicide Development Outline Past: Where we ve been Present: Where we are Future:
More informationWhat do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women
What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women 6 August 2014, Lilongwe Question #1 HIV testing and safety
More informationASLM Anti-microbial Resistance in Africa and Global Health Security. 9TH INTEREST WORKSHOP May 2015 Harare
ASLM Anti-microbial Resistance in Africa and Global Health Security 9TH INTEREST WORKSHOP 2015 8 May 2015 Harare Recent Jim O Neil Report commissioned by the UK government predicts dire consequences of
More informationBiomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013
Biomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013 Community Education Team The AIDS Institute/AIDS Alliance Be the Generation to End the AIDS Epidemic bethegeneration.nih.gov www.aids-alliance.org/education/vaccine
More informationLetter from the CEO. Dear Friends of IAVI,
IAVI Annual Report 2017 Letter from the CEO Dear Friends of IAVI, We are pleased to present an overview of the progress IAVI and partners have made in 2017 toward our pursuit of the development of vaccines
More informationProgramme. Co-Chairs. Take the conversation further online follow AIDS #AIDS2016
EVIDENCE TOACTION This session will highlight the essential role that collaborative research plays in improving public sector policies and services for HIV treatment and prevention. Across southern Africa
More informationPlanning, Priority Setting, and Budget Development for NIH AIDS Research
Planning, Priority Setting, and Budget Development for NIH AIDS Research Robert W. Eisinger, Ph.D. Office of AIDS Research s of Health Focus of Presentation Overview of OAR Priority Setting Process Budget
More informationCombination prevention: Public health and human rights imperatives
Combination prevention: Public health and human rights imperatives Gottfried Hirnschall, MD MPH HIV/AIDS Department WHO, Geneva London, June 11, 2012 Outline The epidemic and response What is combination
More informationTRANS-NIH PLAN FOR HIV RELATED RESEARCH
National Institutes of Health FY 2018 TRANS-NIH PLAN FOR HIV RELATED RESEARCH Prepared by the Office of AIDS Research Maureen M. Goodenow, Ph.D. NIH Associate Director for AIDS Research and Director, Office
More informationInstitute of Medicine. The President s Emergency Plan Strategic Information April 21, 2005
Institute of Medicine The President s Emergency Plan Strategic Information April 21, 2005 Questions of Interest What is the framework to evaluate The Emergency Plan? Measuring impact and outcomes Evidence-based
More informationSuraj Madoori, Treatment Action Group, U.S. and Global Health Policy Director. On behalf of the Tuberculosis Roundtable
United States House of Representatives Committee on Appropriations Subcommittee on State and Foreign Operations and Related Programs Fiscal Year 2020 Written Testimony Suraj Madoori, Treatment Action Group,
More informationThe Global Fund & UNICEF Partnership
The Global Fund & UNICEF Partnership Prof Michel D. Kazatchkine Executive Director UNICEF Executive Board February 9 th, 2011 The Global Fund Millennium Development Goals 1. Eradicate extreme poverty and
More informationBreaking down barriers: HIV interventions in sub-saharan Africa
22 nd International AIDS Conference 23-27 July 2018 Amsterdam, the Netherlands Breaking down barriers: HIV interventions in sub-saharan Africa EDCTP-SAMRC Joint satellite symposium 26 July 2018 07:00-08:30
More informationSOUTH AFRICA S TB BURDEN - OVERVIEW
SOUTH AFRICA S TB BURDEN - OVERVIEW Dr Aaron Motsoaledi, MP: Chairperson of the Board, Stop TB Partnership Minister of Health, South Africa 31 January 2014, Cape Town South Africa s TB Burden Global TB
More informationBUDGET AND RESOURCE ALLOCATION MATRIX
Strategic Direction/Function ILO Strengthened capacity of young people, youth-led organizations, key service providers and partners to develop, implement, monitor and evaluate HIV prevention programmes
More informationAccelerating Children s HIV Treatment (ACT): Rationale, Progress & Challenges
Accelerating Children s HIV Treatment (ACT): Rationale, Progress & Challenges George Siberry, MD, MPH OGAC Senior Technical Advisor for Pediatrics March, 2016 Compared to Adults, Children (
More informationDST-NRF Centre of Excellence in HIV Prevention
DST-NRF Centre of Excellence in HIV Prevention RESEARCH: IMPACTING POLICY & PRACTICE women, especially young women, in South Africa. The CoE focuses on research and development of new prevention technologies
More informationTowards universal access
Key messages Towards universal access Scaling up priority HIV/AIDS interventions in the health sector September 2009 Progress report Towards universal access provides a comprehensive global update on progress
More informationGlobal Pediatric AIDS: at the Tipping Point. Mark W. Kline, M.D. Professor of Pediatrics Chief, Retrovirology President and Chair, BIPAI
Global Pediatric AIDS: at the Tipping Point Mark W. Kline, M.D. Professor of Pediatrics Chief, Retrovirology President and Chair, BIPAI Objectives Describe the impact of HIV/AIDS on the health of children
More informationREDUCING STRUCTURAL BARRIERS TO SCHOOLING: A MEANS TO REDUCE HIV RISK?
REDUCING STRUCTURAL BARRIERS TO SCHOOLING: A MEANS TO REDUCE HIV RISK? Audrey Pettifor, PhD MPH Department of Epidemiology, University of North Carolina Overview Epidemiology of HIV in young people Evidence
More informationProgram Overview. Supported by PEPFAR/HRSA Grant Number U91HA06801
Program Overview Supported by PEPFAR/HRSA Grant Number U91HA06801 Program Goal To contribute to health systems strengthening in African partner countries by developing a leadership training program targeting
More informationThe HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA)
Written Testimony for the Record to the House Subcommittee on Labor, Health and Human Services, Education and Related Agencies regarding FY 2018 Appropriations for HIV/AIDS Programs Submitted by Dr. Wendy
More informationMDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT
TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words
More informationLessons learned from the IeDEA West Africa Collaboration
Lessons learned from the IeDEA West Africa Collaboration François DABIS with the contribution of Didier Koumavi EKOUEVI INSERM U-897, Bordeaux, France, Programme PACCI, ANRS site, Abidjan, Côte d Ivoire
More informationA Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP)
A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP) Delivette Castor, PhD USAID Jason Reed, MD, MPH Jhpiego Timothy Mah, DSc USAID Global Health Mini-University September 14, 2017 Presentation
More informationMid-term Review of the UNGASS Declaration of. Commitment on HIV/AIDS. Ireland 2006
Mid-term Review of the UNGASS Declaration of Commitment on HIV/AIDS Ireland 2006 Irish Role in Global Response Just as the HIV/AIDS epidemic is a global threat, addressing the challenge of the epidemic
More informationWhat Do We Really Mean By Adherence in Vaginal Microbicide Trials?
What Do We Really Mean By Adherence in Vaginal Microbicide Trials? A COMPARATIVE STUDY International Conference on HIV Treatment and Prevention Adherence June 9 th, 2014 Miami, USA Lori Miller, MHS PhD
More informationHIV: A global perspective on epidemiology, diagnosis and prevention
HIV: A global perspective on epidemiology, diagnosis and prevention Margaret McLees, M.D., DTMH Instructor, Division of Infectious Diseases Denver Health University of Colorado November 13, 2012 Outline
More informationProgress Report: Universal Access Target Setting in East and Southern Africa
Progress Report: Universal Access Target Setting in East and Report prepared by: Team for East & 15 September 2006 For all inquiries please contact Mark Stirling, Regional Director for Eastern and, at
More informationRAPID DIAGNOSIS AND TREATMENT OF MDR-TB
RAPID DIAGNOSIS AND TREATMENT OF MDR-TB FORMING PARTNERSHIPS TO STRENGTHEN THE GLOBAL RESPONSE TO MDR-TB - WHERE IT MATTERS MOST I am delighted that this initiative will improve both the technology needed
More informationImpact of the Proposed Cuts to HIV/AIDS Research. Kevin Fisher AVAC September 7, 2017
Impact of the Proposed Cuts to HIV/AIDS Research Kevin Fisher AVAC September 7, 2017 President s FY18 Budget Cuts $544 m from the FY 2017 NIH HIV/AIDS research budget levels A cut of 18.5% FY 18 Cut FY
More information